Dilaforette, a Swedish company received Orphan Drug Designation from the FDA for sevuparin (DF02) for the treatment of patients with sicke-cell disease (SCD). Sevuparin is a heparan sulphate mimetic designed to retain the anti-adhesive effects of heparin, while reducing the anti-coagulant properties. SCD is a rare genetic disease with significant unmet medical need. Sevuparin offers treatment of the underlying cause of vaso-occlusive crisis (VOC) leading to improvement of quality of life for SCD patients. Dilaforette is currently in the final stage of preparation for a Phase II study and aim to start recruitment of patients during the first half of 2015.